Millipore Releases AdenoSilence™ Vectors for RNAi Delivery

Millipore Corporation today announced the launch of the first round of adenoviral shRNA expression vector reagents targeting the human druggable genome.

The classes that are included in this release represent all the major protein classes amenable to small molecule intervention, including kinases, GPCRs, ion channels, proteases, nuclear hormone receptors, secreted proteins and receptors. The targets were chosen to complement Millipore’s current offering of drug discovery-based products and services.

These AdenoSilence vectors are available in three different sequence variants sold individually or as a kit containing all three variants. A replication incompetent version of the human adenovirus is used to introduce shRNA into a broad range of primary cells that decrease the expression of the targeted genes. Human primary cells are the best systems to model disease and work well in target discovery programs.

AdenoSilence vectors allow for single step delivery of shRNA through the direct application of the virus supernatants onto a primary cell culture, thereby making any additional transfection reagents or complex transfection protocols unnecessary. AdenoSilence reagents are highly efficient and typically silence the gene of interest for more than 10 days. This extended knockdown duration supports longer-term assay protocols, such as differentiation assays, and simplifies the scheduling of assay runs.

This product is a result of a distribution agreement announced earlier this year between Millipore Corporation and BioFocus DPI, the drug discovery service division of Galapagos NV. Millipore provides complete solutions for RNAi experimentation by offering products to deliver the RNAi reagent, measure the knockdown, and analyze the downstream effects with functional assays.